Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC.

Science. 2006 Apr 7;312(5770):117-21.

2.

Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.

Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):911-7. doi: 10.1161/ATVBAHA.114.305150. Epub 2015 Jan 22.

3.

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Gambarin FI, Favalli V, Serio A, Regazzi M, Pasotti M, Klersy C, Dore R, Mannarino S, Viganò M, Odero A, Amato S, Tavazzi L, Arbustini E.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):354-62. doi: 10.2459/JCM.0b013e3283232a45.

PMID:
19430350
4.

Medicine. Old drug, new hope for Marfan syndrome.

Travis J.

Science. 2006 Apr 7;312(5770):36-7. No abstract available.

PMID:
16601163
5.

miR-29b participates in early aneurysm development in Marfan syndrome.

Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N, Tsao PS, Iosef C, Berry GJ, Mohr FW, Spin JM, Alvira CM, Robbins RC, Fischbein MP.

Circ Res. 2012 Jan 20;110(2):312-24. doi: 10.1161/CIRCRESAHA.111.253740. Epub 2011 Nov 23.

6.

Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.

Yang HH, Kim JM, Chum E, van Breemen C, Chung AW.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):305-312.e2. doi: 10.1016/j.jtcvs.2009.10.039. Epub 2010 Feb 26.

7.

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC.

Nat Med. 2007 Feb;13(2):204-10. Epub 2007 Jan 21. Erratum in: Nat Med. 2007 Apr;13(4):511.

8.

Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?

Matt P, Habashi J, Carrel T, Cameron DE, Van Eyk JE, Dietz HC.

J Thorac Cardiovasc Surg. 2008 Feb;135(2):389-94. doi: 10.1016/j.jtcvs.2007.08.047. Review.

9.

AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?

Mallat Z, Daugherty A.

Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):e10-2. doi: 10.1161/ATVBAHA.114.305173. Epub 2014 Dec 30. No abstract available.

10.

Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.

Takeda N, Yagi H, Hara H, Fujiwara T, Fujita D, Nawata K, Inuzuka R, Taniguchi Y, Harada M, Toko H, Akazawa H, Komuro I.

Int Heart J. 2016 May 25;57(3):271-7. doi: 10.1536/ihj.16-094. Epub 2016 May 13. Review.

11.

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC.

Science. 2011 Apr 15;332(6027):361-5. doi: 10.1126/science.1192152.

12.

Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F.

Hum Mol Genet. 2010 Dec 15;19(24):4790-8. doi: 10.1093/hmg/ddq409. Epub 2010 Sep 24. Erratum in: Hum Mol Genet. 2014 Nov 15;23(22):6137.

13.

Therapy insight: aortic aneurysm and dissection in Marfan's syndrome.

Ramirez F, Dietz HC.

Nat Clin Pract Cardiovasc Med. 2004 Nov;1(1):31-6. Review.

PMID:
16265257
14.

Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.

Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M; COMPARE study group.

Trials. 2010 Jan 12;11:3. doi: 10.1186/1745-6215-11-3.

15.

Paternal fibrillin-1 mutation transmitted to an affected son with neonatal marfan syndrome: the importance of early recognition.

Elshershari H, Harris C.

Cardiol Young. 2014 Aug;24(4):735-8. doi: 10.1017/S1047951113001029. Epub 2013 Aug 9.

PMID:
23930893
16.

Antagonism of GxxPG fragments ameliorates manifestations of aortic disease in Marfan syndrome mice.

Guo G, Muñoz-García B, Ott CE, Grünhagen J, Mousa SA, Pletschacher A, von Kodolitsch Y, Knaus P, Robinson PN.

Hum Mol Genet. 2013 Feb 1;22(3):433-43. doi: 10.1093/hmg/dds439. Epub 2012 Oct 24.

PMID:
23100322
17.

Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.

Kalluri R, Han Y.

Dev Cell. 2008 Jul;15(1):1-2. doi: 10.1016/j.devcel.2008.06.005.

18.

[Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients].

Perrino C, Schiattarella GG, Bottino R, Magliulo F, Oliveti M, Esposito G, Trimarco B.

G Ital Cardiol (Rome). 2014 Jul-Aug;15(7-8):408-17. doi: 10.1714/1596.17416. Review. Italian.

PMID:
25174594
19.

Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade.

Moltzer E, te Riet L, Swagemakers SM, van Heijningen PM, Vermeij M, van Veghel R, Bouhuizen AM, van Esch JH, Lankhorst S, Ramnath NW, de Waard MC, Duncker DJ, van der Spek PJ, Rouwet EV, Danser AH, Essers J.

PLoS One. 2011;6(8):e23411. doi: 10.1371/journal.pone.0023411. Epub 2011 Aug 9.

20.

Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC.

Science. 2011 Apr 15;332(6027):358-61. doi: 10.1126/science.1192149.

Supplemental Content

Support Center